Novo Nordisk subsidiary to build $220M API facility for chronic disease drugs
Novo Nordisk Pharmatech is building a new facility in Denmark to expand capacity for raw material production due to “significantly higher demand” from its parent company. “This is the largest...
View ArticleAN2’s poison pill; Pfizer shares promising mid-stage data for flu shot
Plus, news about Vericel: AN2 Therapeutics adopts poison pill: The small molecule drugmaker put forth the stockholder rights plan for a year after one of its investors — BML Investment Partners —...
View ArticleQ&A: Lykos just cut 75% of its workforce after an FDA rejection. Here’s what...
In the span of a week, Lykos Therapeutics has been rejected by the FDA, had three published papers retracted, dealt with a boardroom shakeup and, yesterday, cut 75% of its roughly 100 employees. It’s a...
View ArticleClik here to view.
Avantor sells off CRO for $650M to private equity firm
Audax Private Equity is buying Avantor’s CRO business for about $650 million. The deal, announced Friday, is for Avantor’s clinical services business, which includes kitting, biorepository and related...
View ArticleClik here to view.
Carbon Health CEO Eren Bali steps down
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Eren Bali has left his position as CEO of the urgent and primary care startup Carbon Health, the company...
View ArticleFDA approves AstraZeneca’s Imfinzi before and after lung cancer surgery
The FDA approved AstraZeneca’s checkpoint inhibitor Imfinzi for use in certain lung cancers before and after surgery, as the pharma company follows in the footsteps of Merck’s Keytruda. The approval...
View ArticleClik here to view.
Medicare negotiations have concluded. What's next for court cases against the...
Multiple drugmakers say they are sticking with their legal strategies against the Inflation Reduction Act even though they agreed to negotiated prices for their therapies. The Centers for Medicare...
View ArticleUnpacking IRA price negotiations results; Lykos’ tough week; Genentech...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleTYK Medicines seeks to launch new EGFR drug in China with $74M Hong Kong IPO
A Chinese drugmaker claiming to one-up AstraZeneca’s blockbuster EGFR inhibitor is slated to jump on the Hong Kong stock exchange after raising about $74 million from an IPO. TYK Medicines, which goes...
View ArticleQ&A: Lilly’s top scientists on genetic medicine ambitions, and how they’re...
Last week, Eli Lilly opened the doors of its new research center in Boston, largely focused on genetic therapies. While the Indianapolis-based drugmaker’s $875 billion valuation largely stems from its...
View ArticleAvidity’s upsized $345M offering; Janus Henderson’s new $150M biotech fund
Plus, news about Phathom and CANbridge: Avidity Biosciences closes $345.1M offering: The raise comes on the heels of Phase 1/2 data earlier this month that showed its RNA drug candidate generated a 25%...
View ArticleBioNTech, MediLink to resume trial enrollment for HER3 antibody-drug...
The FDA on Thursday lifted a partial clinical hold on an early-stage study of a HER3-targeting antibody-drug conjugate that BioNTech is developing with China-based MediLink Therapeutics. The hold,...
View ArticleClik here to view.
Walgreens nabs $100M BARDA partnership to expand decentralized clinical trials
Walgreens has snagged US government funding to expand its clinical trial capabilities, continuing investment where others have dropped off. The retail pharmacy is partnering with the US Biomedical...
View ArticleLiquidia scores only tentative approval for Yutrepia due to Tyvaso exclusivity
Liquidia’s stock $LQDA plummeted nearly 30% on Monday following the company’s announcement that while the FDA had granted a tentative approval for its treprostinil inhalation powder, it won’t get final...
View ArticlePfizer brings Indian generics maker to court over Xeljanz patent
Pfizer filed suit against an Indian pharmaceutical company on Friday over its application to market generic versions of Xeljanz XR. Xeljanz XR is an extended-release version of Pfizer’s blockbuster JAK...
View ArticleHalf of IRA negotiation savings to come from three drugs, Brookings finds
For the first 10 drug prices negotiated under the Inflation Reduction Act, about one-half of the estimated $6 billion in Medicare savings is the result of negotiations for just three of those drugs,...
View ArticleClik here to view.
Eli Lilly's tirzepatide wins in Phase 3 pre-diabetes trial
After recently reporting soaring sales of its diabetes franchise, Eli Lilly is back with more data on its GLP-1/GIP dual agonist tirzepatide. In a Phase 3 trial, the drug reduced the risk of developing...
View ArticleMerck exercises option on one Kelun ADC, returns another as it tweaks broad deal
More than two years into its partnership with China’s Kelun-Biotech, Merck has made further choices on which part of the sprawling early-stage pipeline it wants to move forward. The pharma giant will...
View ArticleClik here to view.
J&J buys another medtech company, this time paying $600M upfront for...
In its fifth acquisition of the year, Johnson & Johnson is again tapping into the medical technology field, which has become a bigger part of its business. The New Jersey healthcare conglomerate...
View ArticleClik here to view.
TCGX and JPM help Pathalys raise $105M to go up against Amgen in subset of...
North Carolina biotech Pathalys Pharma expects to do a rare thing with its nine-figure Series B: file for FDA approval. Whereas most Series B financing rounds get a biotech into Phase 1 or through...
View Article